Endothelial metabolic reprogramming influences tumor immune microenvironment

doi:10.5306/wjco.v17.i3.113326

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 3

This Article

(42)

(0)

(16)

(843)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Mar 24, 2026; 17(3): 113326
Published online Mar 24, 2026. doi: 10.5306/wjco.v17.i3.113326

Table 2 Ongoing or completed clinical trials of anti-angiogenic therapy in combination with immunotherapy

Inhibitor	Clinical stage	Study status	Conditions	Intervention	Ref.
Anlotinib	II	Recruiting	NSCLC	In combination with penpulimab	NCT06341530
Anlotinib	II	Recruiting	Breast cancer	In combination with sintilimab and chemotherapy	NCT04877821
Apatinib	II	Ongoing	Solid tumor	In combination with adebrelimab and microwave ablation	NCT06537505
Axitinib	II	Completed	Advanced melanoma	In combination with nivolumab	NCT04493203
Bevacizumab	I/II	Completed	Malignant solid tumor	In combination with NK immunotherapy	NCT02857920
	II	Completed	Colorectal cancer	In combination with atezolizumab and chemotherapy	NCT02873195
	I/II	Recruiting	Ovarian cancer	In combination with oregovomab and chemotherapy	NCT04938583
	II/III	Recruiting	Colorectal cancer liver metastases	In combination with serplulimab and chemotherapy	NCT06280495
	II	Recruiting	Gastric cancer	In combination with neoadjuvant chemotherapy and PD-1 mAb	NCT06371586
	II	Recruiting	Recurrent TNBC	In combination with pembrolizumab and chemotherapy	NCT06976944
	IV	Ongoing	Advanced melanoma	In combination with iparomlimab and tuvonralimab	NCT07004335
Ramucirumab	II	Recruiting	Gastric cancer	In combination with pembrolizumab and chemotherapy	NCT04069273
Sorafenib	II	Completed	Hepatocellular carcinoma	In combination with PD-1 mAb	NCT04518852

NSCLC: Non-small cell lung cancer; NK: Natural killer; PD-1: Programmed cell death-1; mAb: Monoclonal antibody; TNBC: Triple negative breast cancer.

Full Size Table

Citation: Chen M, Chen ZG. Endothelial metabolic reprogramming influences tumor immune microenvironment. World J Clin Oncol 2026; 17(3): 113326
URL: https://www.wjgnet.com/2218-4333/full/v17/i3/113326.htm
DOI: https://dx.doi.org/10.5306/wjco.v17.i3.113326

Chen M, Chen ZG. Endothelial metabolic reprogramming influences tumor immune microenvironment. World J Clin Oncol 2026; 17(3): 113326 [DOI: 10.5306/wjco.v17.i3.113326]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.